Chromatography purification of canine adenoviral vectors

Human Gene Therapy Methods

Volumn 23, Issue 3, 2012, Pages 182-197

  Segura, María Mercedes ^a   Puig, Meritxell ^a   Monfar, Mercè ^a   Chillón, Miguel ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DEOXYRIBONUCLEASE; RECOMBINANT VACCINE;

ADHERENT CELL; ANIMAL CELL; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CANINE ADENOVIRUS; CELL FRACTIONATION; CELL VIABILITY; CLINICAL EVALUATION; CROSSFLOW FILTRATION; CYTOPATHOGENIC EFFECT; DIAFILTRATION; DOWNSTREAM PROCESSING; ELECTROPHORESIS; GENE EXPRESSION SYSTEM; GENE THERAPY; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; HYDROPHOBICITY; LIMIT OF QUANTITATION; MEMBRANE FILTER; MICROCAPSULE; MICROFILTRATION; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN DEGRADATION; SPECTROPHOTOMETRY; STATIC ELECTRICITY; SUPERNATANT; TRANSMISSION ELECTRON MICROSCOPY; ULTRACENTRIFUGATION; ULTRAFILTRATION; VACCINATION; VIRUS CAPSID; VIRUS ISOLATION; VIRUS MORPHOLOGY; VIRUS PARTICLE; VIRUS PURIFICATION; ANIMAL; CELL LINE; DOG; EVALUATION; FILTRATION; GENE VECTOR; GENETICS; ION EXCHANGE CHROMATOGRAPHY; ISOLATION AND PURIFICATION; METHODOLOGY; POLYMERASE CHAIN REACTION; ULTRASTRUCTURE; VIRION;

ADENOVIRUSES, CANINE; ANIMALS; CELL LINE; CHROMATOGRAPHY, ION EXCHANGE; DOGS; ELECTROPHORESIS; FILTRATION; GENETIC THERAPY; GENETIC VECTORS; MICROSCOPY, ELECTRON, TRANSMISSION; POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; VIRION;

EID: 84872023482     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2012.058     Document Type: Article

References (52)

1. Alcayaga-Miranda, F., Cascallo, M., Rojas, J.J., et al. (2010). Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies. Cancer Gene Ther. 17, 792-802.
2. Altaras, N.E., Aunins, J.G., Evans, R.K., et al. (2005). Production and formulation of adenovirus vectors. Adv. Biochem. Eng. Biotechnol. 99, 193-260. (Pubitemid 44617182)
3. Bouet-Cararo, C., Contreras, V., Fournier, A., et al. (2011). Canine adenoviruses elicit both humoral and cell-mediated immune responses against rabies following immunisation of sheep. Vaccine 29, 1304-1310.
4. Bru, T., Salinas, S., and Kremer, E.J. (2010). An update on canine adenovirus type 2 and its vectors. Viruses 2, 2134-2153.
5. Brunetti-Pierri, N., Palmer, D.J., Beaudet, A.L., et al. (2004). Acute toxicity after high-dose systemic injection of helperdependent adenoviral vectors into nonhuman primates. Hum. Gene Ther. 15, 35-46. (Pubitemid 38147187)
6. Burova, E., and Ioffe, E. (2005). Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications. Gene Ther. 12(Suppl. 1), S5-S17. (Pubitemid 41541749)
7. Cornwell, H.J., Koptopoulos, G., Thompson, H., et al. (1982). Immunity to canine adenovirus respiratory disease: a comparison of attenuated CAV-1 and CAV-2 vaccines. Vet. Rec. 110, 27-32. (Pubitemid 12181351)
8. Duffy, A.M., O'Doherty, A.M., O'Brien, T., et al. (2005). Purification of adenovirus and adeno-associated virus: comparison of novel membrane-based technology to conventional techniques. Gene Ther. 12(Suppl. 1), S62-S72. (Pubitemid 41541754)
9. Green, A.P., Huang, J.J., Scott, M.O., et al. (2002). A new scalable method for the purification of recombinant adenovirus vectors. Hum. Gene Ther. 13, 1921-1934. (Pubitemid 35341034)
10. Hemminki, A., Kanerva, A., Kremer, E.J., et al. (2003). A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol. Ther. 7, 163-173. (Pubitemid 36395351)
11. Henderson, H., Jackson, F., Bean, K., et al. (2009). Oral immunization of raccoons and skunks with a canine adenovirus recombinant rabies vaccine. Vaccine 27, 7194-7197.
12. Hu, R., Zhang, S., Fooks, A.R., et al. (2006). Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein. Microbes Infect. 8, 1090-1097.
13. Hu, R.L., Liu, Y., Zhang, S.F., et al. (2007). Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies. Vaccine 25, 5301-5307. (Pubitemid 46977543)
14. Hutchins, B. (2002). Development of a Reference Material for Characterizing Adenovirus Vectors. Bioprocess. J. 1, 25-29.
15. Huyghe, B.G., Liu, X., Sutjipto, S., et al. (1995). Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum. Gene Ther. 6, 1403-1416.
16. Kamen, A., and Henry, O. (2004). Development and optimization of an adenovirus production process. J. Gene Med. 6(Suppl. 1), S184-S192. (Pubitemid 40228027)
17. Konz, J.O., Lee, A.L., Lewis, J.A., et al. (2005a). Development of a purification process for adenovirus: controlling virus aggregation to improve the clearance of host cell DNA. Biotechnol. Prog. 21, 466-472. (Pubitemid 40466419)
18. Konz, J.O., Livingood, R.C., Bett, A.J., et al. (2005b). Serotype specificity of adenovirus purification using anion-exchange chromatography. Hum. Gene Ther. 16, 1346-1353. (Pubitemid 41611663)
19. Kremer, E.J. (2004). CAR chasing: canine adenovirus vectors-all bite and no bark? J. Gene Med. 6(Suppl. 1), S139-S151. (Pubitemid 40228023)
20. Kremer, E.J., Boutin, S., Chillon, M., et al. (2000). Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J. Virol. 74, 505-512. (Pubitemid 30002932)
21. Lau, A.A., Hopwood, J.J., Kremer, E.J., et al. (2010). SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors. Mol. Genet. Metab. 100, 168-175.
22. Lau, A.A., Rozaklis, T., Ibanes, S., et al. (2012). Helper-dependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder. Gene 491, 53-57.
23. Liu, Y., Zhang, S., Ma, G., et al. (2008). Efficacy and safety of a live canine adenovirus-vectored rabies virus vaccine in swine. Vaccine 26, 5368-5372.
24. Lock, M., Alvira, M.R., and Wilson, J.M. (2012). Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography. Hum. Gene Ther. Methods 23, 56-64.
25. Lusky,M. (2005). Good manufacturing practice production of adenoviral vectors for clinical trials. Hum. Gene Ther. 16, 281-291. (Pubitemid 40471888)
26. Lyddiatt, A., and O'Sullivan, D.A. (1998). Biochemical recovery and purification of gene therapy vectors. Curr. Opin. Biotechnol. 9, 177-185.
27. Maizel, J.V., Jr., White, D.O., and Scharff, M.D. (1968). The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36, 115-125.
28. Mittereder, N., March, K.L., and Trapnell, B.C. (1996). Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70, 7498-7509. (Pubitemid 26339054)
29. Muruve, D.A., Barnes, M.J., Stillman, I.E., et al. (1999). Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10, 965-976. (Pubitemid 29195426)
30. Peixoto, C., Ferreira, T.B., Carrondo, M.J., et al. (2006). Purification of adenoviral vectors using expanded bed chromatography. J. Virol. Methods 132, 121-126. (Pubitemid 43220170)
31. Peixoto, C., Ferreira, T.B., Sousa, M.F., et al. (2008). Towards purification of adenoviral vectors based on membrane technology. Biotechnol. Prog. 24, 1290-1296.
32. Peltekian, E., Garcia, L., and Danos, O. (2002). Neurotropism and retrograde axonal transport of a canine adenoviral vector: a tool for targeting key structures undergoing neurodegenerative processes. Mol. Ther. 5, 25-32. (Pubitemid 34110477)
33. Perreau, M., and Kremer, E.J. (2006). The conundrum between immunological memory to adenovirus and their use as vectors in clinical gene therapy. Mol. Biotechnol. 34, 247-256. (Pubitemid 46030398)
34. Piedra, P.A., Poveda, G.A., Ramsey, B., et al. (1998). Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 101, 1013-1019. (Pubitemid 28248886)
35. Qu, G., Bahr-Davidson, J., Prado, J., et al. (2007). Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J. Virol. Methods 140, 183-192. (Pubitemid 46185608)
36. Schagen, F.H., Rademaker, H.J., Rabelink, M.J., et al. (2000). Ammonium sulphate precipitation of recombinant adenovirus from culture medium: an easy method to increase the total virus yield. Gene Ther. 7, 1570-1574.
37. Schnell,M.A., Zhang, Y., Tazelaar, J., et al. (2001). Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. 3, 708-722. (Pubitemid 32509868)
38. Segura, M.M., Alba, R., Bosch, A., et al. (2008). Advances in helper-dependent adenoviral vector research. Curr. Gene Ther. 8, 222-235.
39. Segura, M.M., Monfar, M., Puig, M., et al. (2010). A real-time PCR assay for quantification of canine adenoviral vectors. J. Virol. Methods 163, 129-136.
40. Segura, M.M., Kamen, A.A., and Garnier, A. (2011). Overview of current scalable methods for purification of viral vectors. Methods Mol. Biol. 737, 89-116.
41. Simek, S., Byrnes, A., and Bauer, S. (2002). FDA perspective on the use of the adenovirus reference material. Bioprocess. J. 1, 40-42.
42. Smith, B.F., Curiel, D.T., Ternovoi, V.V., et al. (2006). Administration of a conditionally replicative oncolytic canine adenovirus in normal dogs. Cancer Biother. Radiopharm. 21, 601-606. (Pubitemid 46175697)
43. Soudais, C., Boutin, S., Hong, S.S., et al. (2000). Canine adenovirus type 2 attachment and internalization: coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway. J. Virol. 74, 10639-10649.
44. Soudais, C., Laplace-Builhe, C., Kissa, K., and Kremer, E.J. (2001). Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo. FASEB J. 15, 2283-2285.
45. Sutjipto, S., Ravindran, S., Cornell, D., et al. (2005). Characterization of empty capsids from a conditionally replicating adenovirus for gene therapy. Hum. Gene Ther. 16, 109-125. (Pubitemid 40250337)
46. Tancevski, I., Wehinger, A., Patsch, J.R., and Ritsch, A. (2006). In vivo application of adenoviral vectors purified by a Taqman Real Time PCR-supported chromatographic protocol. Int. J. Biol. Macromol. 39, 77-82. (Pubitemid 44066541)
47. Urabe, M., Xin, K.Q., Obara, Y., et al. (2006). Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression. Mol. Ther. 13, 823-828.
48. Vellekamp, G., Porter, F.W., Sutjipto, S., et al. (2001). Empty capsids in column-purified recombinant adenovirus preparations. Hum. Gene Ther. 12, 1923-1936. (Pubitemid 32947235)
49. Wadell, G. (1972). Sensitization and neutralization of adenovirus by specific sera against capsid subunits. J. Immunol. 108, 622-632.
50. Wolff, W., and Reichl, U. (2011). Downstream processing of cell culture-derived virus particles. Expert Rev. Vaccines 10, 1451-1475.
51. Zhang, Y., and Bergelson, J.M. (2005). Adenovirus receptors. J. Virol. 79, 12125-12131. (Pubitemid 41346076)
52. Zhang, Y., Chirmule, N., Gao, G.P., et al. (2001). Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 3, 697-707. (Pubitemid 32509867)